David Kao
Concepts (373)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 35 | 2026 | 2314 | 4.980 |
Why?
| | Machine Learning | 8 | 2025 | 585 | 2.250 |
Why?
| | Stroke Volume | 17 | 2025 | 648 | 1.900 |
Why?
| | Adrenergic beta-Antagonists | 10 | 2025 | 250 | 1.540 |
Why?
| | Methadone | 5 | 2023 | 110 | 1.460 |
Why?
| | Pregnancy Complications, Cardiovascular | 5 | 2022 | 83 | 1.430 |
Why?
| | Buprenorphine | 3 | 2023 | 181 | 1.330 |
Why?
| | Cardiomyopathies | 5 | 2022 | 337 | 1.310 |
Why?
| | United States Food and Drug Administration | 5 | 2024 | 203 | 1.210 |
Why?
| | Decision Support Systems, Clinical | 6 | 2024 | 265 | 1.160 |
Why?
| | Pharmacogenetics | 5 | 2024 | 172 | 1.120 |
Why?
| | Cardiomyopathy, Dilated | 9 | 2025 | 359 | 1.120 |
Why?
| | Adverse Drug Reaction Reporting Systems | 4 | 2024 | 81 | 1.080 |
Why?
| | Arrhythmias, Cardiac | 6 | 2023 | 360 | 1.050 |
Why?
| | Cytochrome P-450 CYP2C19 | 4 | 2024 | 26 | 0.970 |
Why?
| | Electronic Health Records | 7 | 2024 | 1169 | 0.960 |
Why?
| | Propanolamines | 3 | 2019 | 40 | 0.900 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2024 | 434 | 0.860 |
Why?
| | Hospitalization | 10 | 2024 | 2424 | 0.840 |
Why?
| | Workflow | 2 | 2026 | 184 | 0.830 |
Why?
| | Telemedicine | 4 | 2024 | 940 | 0.750 |
Why?
| | Atrial Fibrillation | 5 | 2026 | 548 | 0.740 |
Why?
| | Torsades de Pointes | 4 | 2016 | 23 | 0.720 |
Why?
| | Seasons | 1 | 2024 | 556 | 0.710 |
Why?
| | Pulmonary Edema | 1 | 2021 | 106 | 0.690 |
Why?
| | Humans | 88 | 2026 | 144261 | 0.690 |
Why?
| | Coffee | 1 | 2021 | 15 | 0.670 |
Why?
| | Pharmacogenomic Testing | 4 | 2022 | 62 | 0.650 |
Why?
| | Stroke | 2 | 2021 | 1254 | 0.630 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2024 | 497 | 0.630 |
Why?
| | Aged | 33 | 2026 | 25850 | 0.610 |
Why?
| | Defibrillators, Implantable | 2 | 2021 | 382 | 0.610 |
Why?
| | Artificial Intelligence | 2 | 2026 | 365 | 0.600 |
Why?
| | Prosthesis Failure | 1 | 2020 | 125 | 0.590 |
Why?
| | Prosthesis-Related Infections | 1 | 2020 | 99 | 0.580 |
Why?
| | Long QT Syndrome | 3 | 2016 | 69 | 0.580 |
Why?
| | Mobile Applications | 1 | 2021 | 196 | 0.580 |
Why?
| | Spironolactone | 1 | 2019 | 39 | 0.570 |
Why?
| | Device Removal | 1 | 2020 | 142 | 0.570 |
Why?
| | Risk Assessment | 10 | 2026 | 3637 | 0.570 |
Why?
| | United States | 22 | 2025 | 15876 | 0.570 |
Why?
| | Pacemaker, Artificial | 1 | 2020 | 126 | 0.560 |
Why?
| | Medical Records | 2 | 2019 | 186 | 0.560 |
Why?
| | Coronary Disease | 1 | 2021 | 381 | 0.560 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 68 | 0.550 |
Why?
| | Diabetes Mellitus | 2 | 2024 | 1092 | 0.550 |
Why?
| | Biomedical Research | 2 | 2024 | 709 | 0.540 |
Why?
| | Periodicals as Topic | 1 | 2020 | 203 | 0.540 |
Why?
| | Mortality | 3 | 2019 | 371 | 0.530 |
Why?
| | Retrospective Studies | 22 | 2026 | 17009 | 0.530 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2018 | 67 | 0.510 |
Why?
| | Female | 50 | 2026 | 77976 | 0.500 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2017 | 57 | 0.500 |
Why?
| | Hospital Records | 1 | 2016 | 10 | 0.490 |
Why?
| | Proteoglycans | 1 | 2017 | 108 | 0.490 |
Why?
| | Ventricular Function, Left | 5 | 2025 | 538 | 0.480 |
Why?
| | Analgesics, Opioid | 2 | 2023 | 1131 | 0.480 |
Why?
| | Hospital Mortality | 6 | 2024 | 1027 | 0.470 |
Why?
| | Disease Management | 1 | 2020 | 643 | 0.460 |
Why?
| | Survival | 1 | 2015 | 38 | 0.460 |
Why?
| | Tetrazoles | 1 | 2015 | 50 | 0.450 |
Why?
| | Male | 42 | 2026 | 72035 | 0.450 |
Why?
| | Middle Aged | 30 | 2025 | 35762 | 0.450 |
Why?
| | Electrocardiography | 5 | 2026 | 660 | 0.450 |
Why?
| | Biphenyl Compounds | 1 | 2015 | 68 | 0.440 |
Why?
| | Muscle Proteins | 2 | 2025 | 244 | 0.440 |
Why?
| | Myocardial Infarction | 3 | 2018 | 1208 | 0.420 |
Why?
| | Research Design | 1 | 2020 | 1129 | 0.420 |
Why?
| | Ventricular Remodeling | 3 | 2025 | 275 | 0.410 |
Why?
| | Loperamide | 2 | 2023 | 12 | 0.400 |
Why?
| | Myocardium | 3 | 2017 | 939 | 0.390 |
Why?
| | Diet | 1 | 2021 | 1271 | 0.390 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2017 | 2143 | 0.390 |
Why?
| | Tachycardia, Ventricular | 1 | 2015 | 181 | 0.380 |
Why?
| | Registries | 2 | 2020 | 2382 | 0.380 |
Why?
| | Precision Medicine | 6 | 2024 | 456 | 0.380 |
Why?
| | Adult | 28 | 2024 | 40262 | 0.370 |
Why?
| | Legislation, Medical | 1 | 2012 | 11 | 0.370 |
Why?
| | Amiodarone | 1 | 2012 | 31 | 0.370 |
Why?
| | Peripartum Period | 4 | 2022 | 19 | 0.370 |
Why?
| | Phenotype | 5 | 2025 | 3157 | 0.360 |
Why?
| | Patient Readmission | 1 | 2018 | 756 | 0.360 |
Why?
| | Quality Improvement | 2 | 2020 | 1285 | 0.350 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2012 | 141 | 0.340 |
Why?
| | Sex Factors | 4 | 2024 | 2096 | 0.330 |
Why?
| | Pyrazines | 2 | 2008 | 92 | 0.330 |
Why?
| | Catheter Ablation | 1 | 2015 | 353 | 0.330 |
Why?
| | Heart Arrest | 4 | 2019 | 407 | 0.330 |
Why?
| | Cardiovascular Diseases | 5 | 2024 | 2134 | 0.330 |
Why?
| | Treatment Outcome | 10 | 2025 | 11643 | 0.320 |
Why?
| | Transfusion Reaction | 1 | 2011 | 63 | 0.320 |
Why?
| | Forecasting | 2 | 2024 | 388 | 0.320 |
Why?
| | Triazoles | 2 | 2008 | 184 | 0.320 |
Why?
| | Heart-Assist Devices | 1 | 2016 | 567 | 0.320 |
Why?
| | Echocardiography | 3 | 2024 | 647 | 0.320 |
Why?
| | Risk Factors | 10 | 2025 | 10699 | 0.310 |
Why?
| | Postoperative Complications | 2 | 2020 | 2916 | 0.300 |
Why?
| | Insurance, Health | 1 | 2012 | 301 | 0.300 |
Why?
| | Patient Discharge | 2 | 2021 | 977 | 0.300 |
Why?
| | Patient Transfer | 1 | 2012 | 206 | 0.300 |
Why?
| | Anemia | 1 | 2011 | 187 | 0.290 |
Why?
| | Thiazolidinediones | 1 | 2010 | 138 | 0.290 |
Why?
| | Databases, Factual | 5 | 2020 | 1484 | 0.290 |
Why?
| | Genotype | 3 | 2024 | 1833 | 0.290 |
Why?
| | Marketing | 1 | 2008 | 24 | 0.290 |
Why?
| | Rhabdomyolysis | 1 | 2008 | 23 | 0.280 |
Why?
| | Renal Insufficiency | 1 | 2011 | 168 | 0.280 |
Why?
| | Drug Industry | 1 | 2008 | 48 | 0.280 |
Why?
| | Aged, 80 and over | 7 | 2024 | 8243 | 0.280 |
Why?
| | Simvastatin | 1 | 2008 | 59 | 0.280 |
Why?
| | Heart Ventricles | 4 | 2017 | 756 | 0.280 |
Why?
| | Receptors, Adrenergic, beta-1 | 4 | 2019 | 23 | 0.280 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2008 | 46 | 0.280 |
Why?
| | Incidence | 6 | 2025 | 2870 | 0.280 |
Why?
| | Heart Rate | 3 | 2025 | 849 | 0.270 |
Why?
| | Follow-Up Studies | 7 | 2025 | 5389 | 0.270 |
Why?
| | Length of Stay | 4 | 2024 | 1335 | 0.260 |
Why?
| | Cytochrome P-450 CYP2D6 | 3 | 2022 | 32 | 0.260 |
Why?
| | Kaplan-Meier Estimate | 3 | 2016 | 964 | 0.260 |
Why?
| | Proportional Hazards Models | 4 | 2021 | 1322 | 0.260 |
Why?
| | Pharmacovigilance | 2 | 2024 | 23 | 0.250 |
Why?
| | Practice Patterns, Physicians' | 3 | 2020 | 1347 | 0.250 |
Why?
| | Elective Surgical Procedures | 2 | 2020 | 201 | 0.240 |
Why?
| | Biological Specimen Banks | 3 | 2024 | 101 | 0.240 |
Why?
| | Atrial Flutter | 1 | 2026 | 45 | 0.230 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2603 | 0.230 |
Why?
| | Emergency Service, Hospital | 2 | 2020 | 2301 | 0.230 |
Why?
| | Patient Reported Outcome Measures | 2 | 2020 | 487 | 0.220 |
Why?
| | Cause of Death | 2 | 2019 | 464 | 0.220 |
Why?
| | New York | 1 | 2024 | 124 | 0.210 |
Why?
| | Glucose | 1 | 2010 | 1046 | 0.210 |
Why?
| | Diabetic Cardiomyopathies | 1 | 2024 | 34 | 0.210 |
Why?
| | Pandemics | 3 | 2022 | 1682 | 0.210 |
Why?
| | Young Adult | 9 | 2022 | 13990 | 0.200 |
Why?
| | Pregnancy | 6 | 2022 | 7180 | 0.200 |
Why?
| | Diphenoxylate | 1 | 2023 | 5 | 0.200 |
Why?
| | Acute Kidney Injury | 2 | 2008 | 862 | 0.200 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2021 | 1705 | 0.190 |
Why?
| | Adolescent | 10 | 2020 | 22281 | 0.190 |
Why?
| | Nonprescription Drugs | 1 | 2023 | 65 | 0.190 |
Why?
| | Monitoring, Physiologic | 1 | 2024 | 289 | 0.190 |
Why?
| | Heart Defects, Congenital | 2 | 2020 | 913 | 0.180 |
Why?
| | Prognosis | 5 | 2020 | 4278 | 0.180 |
Why?
| | Medicare | 2 | 2020 | 881 | 0.180 |
Why?
| | Algorithms | 4 | 2025 | 1834 | 0.180 |
Why?
| | Naltrexone | 1 | 2023 | 117 | 0.180 |
Why?
| | Insulin Resistance | 1 | 2010 | 1232 | 0.170 |
Why?
| | Speech | 1 | 2021 | 77 | 0.170 |
Why?
| | Red Meat | 1 | 2021 | 17 | 0.170 |
Why?
| | Hypertension | 2 | 2020 | 1254 | 0.170 |
Why?
| | Time Factors | 3 | 2020 | 7155 | 0.170 |
Why?
| | Losartan | 1 | 2020 | 13 | 0.170 |
Why?
| | Lisinopril | 1 | 2020 | 15 | 0.170 |
Why?
| | Drug Dosage Calculations | 1 | 2020 | 27 | 0.170 |
Why?
| | Data Interpretation, Statistical | 2 | 2020 | 371 | 0.170 |
Why?
| | Protective Factors | 1 | 2021 | 99 | 0.160 |
Why?
| | Smartphone | 1 | 2021 | 102 | 0.160 |
Why?
| | Angioedema | 1 | 2020 | 15 | 0.160 |
Why?
| | Actigraphy | 1 | 2021 | 145 | 0.160 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2021 | 63 | 0.160 |
Why?
| | Wearable Electronic Devices | 1 | 2021 | 63 | 0.160 |
Why?
| | American Heart Association | 2 | 2019 | 348 | 0.160 |
Why?
| | Milk | 1 | 2021 | 119 | 0.160 |
Why?
| | Hypoglycemic Agents | 1 | 2010 | 1379 | 0.160 |
Why?
| | Turner Syndrome | 1 | 2021 | 63 | 0.160 |
Why?
| | Data Accuracy | 1 | 2020 | 65 | 0.160 |
Why?
| | Indans | 1 | 2020 | 13 | 0.160 |
Why?
| | Biological Products | 1 | 2023 | 251 | 0.160 |
Why?
| | Oxadiazoles | 1 | 2020 | 37 | 0.160 |
Why?
| | Bionics | 1 | 2019 | 14 | 0.160 |
Why?
| | Editorial Policies | 1 | 2020 | 46 | 0.160 |
Why?
| | California | 2 | 2012 | 469 | 0.160 |
Why?
| | Medical Informatics | 1 | 2020 | 97 | 0.150 |
Why?
| | Referral and Consultation | 2 | 2017 | 847 | 0.150 |
Why?
| | Fingolimod Hydrochloride | 1 | 2020 | 39 | 0.150 |
Why?
| | Medical Futility | 1 | 2019 | 31 | 0.150 |
Why?
| | Medical Record Linkage | 1 | 2020 | 68 | 0.150 |
Why?
| | Software | 2 | 2015 | 690 | 0.150 |
Why?
| | Prescription Drugs | 1 | 2020 | 110 | 0.150 |
Why?
| | Information Storage and Retrieval | 1 | 2020 | 121 | 0.150 |
Why?
| | Drug Overdose | 1 | 2023 | 367 | 0.140 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2020 | 82 | 0.140 |
Why?
| | Sitagliptin Phosphate | 2 | 2008 | 31 | 0.140 |
Why?
| | Medical Order Entry Systems | 1 | 2019 | 40 | 0.140 |
Why?
| | Drug Prescriptions | 1 | 2021 | 280 | 0.140 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2020 | 2026 | 0.140 |
Why?
| | Child Health Services | 1 | 2020 | 185 | 0.140 |
Why?
| | Tobacco Use | 1 | 2019 | 61 | 0.140 |
Why?
| | Cohort Studies | 3 | 2021 | 5935 | 0.140 |
Why?
| | Computer Graphics | 2 | 2015 | 41 | 0.140 |
Why?
| | Cluster Analysis | 1 | 2019 | 519 | 0.140 |
Why?
| | Social Determinants of Health | 1 | 2022 | 299 | 0.140 |
Why?
| | Receptors, Histamine H2 | 1 | 2017 | 6 | 0.140 |
Why?
| | Gene Regulatory Networks | 2 | 2023 | 318 | 0.130 |
Why?
| | Florida | 1 | 2018 | 116 | 0.130 |
Why?
| | Advisory Committees | 1 | 2019 | 227 | 0.130 |
Why?
| | Neisseria gonorrhoeae | 1 | 1997 | 29 | 0.130 |
Why?
| | Porins | 1 | 1997 | 18 | 0.130 |
Why?
| | Dyslipidemias | 1 | 2019 | 171 | 0.130 |
Why?
| | Consensus | 1 | 2019 | 488 | 0.130 |
Why?
| | Prospective Studies | 4 | 2021 | 7970 | 0.130 |
Why?
| | Nursing Assessment | 1 | 2017 | 56 | 0.130 |
Why?
| | Academic Medical Centers | 1 | 2020 | 545 | 0.120 |
Why?
| | Pressure Ulcer | 1 | 2017 | 43 | 0.120 |
Why?
| | Patient Participation | 1 | 2020 | 429 | 0.120 |
Why?
| | Antihypertensive Agents | 1 | 2020 | 509 | 0.120 |
Why?
| | Population Surveillance | 1 | 2020 | 483 | 0.120 |
Why?
| | Heart Diseases | 1 | 2020 | 349 | 0.120 |
Why?
| | Hospitals, Teaching | 1 | 2017 | 119 | 0.120 |
Why?
| | Tilidine | 1 | 2016 | 2 | 0.120 |
Why?
| | Cardiology | 1 | 2019 | 353 | 0.120 |
Why?
| | Genetic Markers | 1 | 2017 | 331 | 0.120 |
Why?
| | Double-Blind Method | 3 | 2025 | 2025 | 0.120 |
Why?
| | Oxycodone | 1 | 2016 | 53 | 0.120 |
Why?
| | Rheumatic Fever | 1 | 2015 | 5 | 0.110 |
Why?
| | Rheumatic Heart Disease | 1 | 2015 | 4 | 0.110 |
Why?
| | Databases, Genetic | 1 | 2017 | 248 | 0.110 |
Why?
| | Sex Distribution | 1 | 2016 | 380 | 0.110 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2015 | 38 | 0.110 |
Why?
| | Cholesterol Ester Transfer Proteins | 1 | 2015 | 22 | 0.110 |
Why?
| | Angiotensin II | 1 | 2015 | 97 | 0.110 |
Why?
| | Hospitals, Low-Volume | 1 | 2015 | 25 | 0.110 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 846 | 0.110 |
Why?
| | Gene Expression Profiling | 3 | 2017 | 1782 | 0.110 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2017 | 758 | 0.110 |
Why?
| | Hospitals, High-Volume | 1 | 2015 | 49 | 0.110 |
Why?
| | Computational Biology | 2 | 2017 | 680 | 0.110 |
Why?
| | Naloxone | 1 | 2016 | 132 | 0.110 |
Why?
| | Marijuana Use | 1 | 2018 | 213 | 0.110 |
Why?
| | Mothers | 1 | 2020 | 774 | 0.110 |
Why?
| | United Kingdom | 1 | 2015 | 336 | 0.110 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2020 | 543 | 0.100 |
Why?
| | Biomarkers | 2 | 2024 | 4254 | 0.100 |
Why?
| | International Classification of Diseases | 1 | 2015 | 143 | 0.100 |
Why?
| | Age Factors | 2 | 2019 | 3313 | 0.100 |
Why?
| | Comorbidity | 1 | 2019 | 1646 | 0.100 |
Why?
| | Chronic Disease | 2 | 2020 | 1812 | 0.100 |
Why?
| | Gene Expression | 2 | 2017 | 1487 | 0.100 |
Why?
| | Down-Regulation | 1 | 2015 | 627 | 0.100 |
Why?
| | MicroRNAs | 2 | 2017 | 700 | 0.100 |
Why?
| | Cholesterol | 1 | 2015 | 399 | 0.100 |
Why?
| | Narcotic Antagonists | 1 | 2015 | 204 | 0.100 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2020 | 390 | 0.100 |
Why?
| | Federal Government | 1 | 2012 | 23 | 0.090 |
Why?
| | Coronary Artery Disease | 1 | 2019 | 741 | 0.090 |
Why?
| | Myocytes, Cardiac | 1 | 2017 | 551 | 0.090 |
Why?
| | Drug Resistance | 1 | 2012 | 153 | 0.090 |
Why?
| | RNA, Messenger | 2 | 2017 | 2829 | 0.090 |
Why?
| | Area Under Curve | 1 | 2012 | 329 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 2 | 2017 | 2359 | 0.090 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 919 | 0.090 |
Why?
| | Colorado | 4 | 2024 | 4562 | 0.090 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 2111 | 0.080 |
Why?
| | Patient Safety | 1 | 2015 | 347 | 0.080 |
Why?
| | Anti-Retroviral Agents | 1 | 2013 | 240 | 0.080 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2012 | 136 | 0.080 |
Why?
| | Opiate Substitution Treatment | 1 | 2013 | 174 | 0.080 |
Why?
| | Bayes Theorem | 1 | 2012 | 433 | 0.080 |
Why?
| | Managed Care Programs | 2 | 2022 | 136 | 0.080 |
Why?
| | Survival Rate | 1 | 2015 | 2088 | 0.080 |
Why?
| | Pregnancy Outcome | 1 | 2013 | 476 | 0.080 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2012 | 237 | 0.080 |
Why?
| | Genome-Wide Association Study | 1 | 2017 | 1406 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2017 | 940 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2012 | 1533 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2917 | 0.070 |
Why?
| | Pharmacogenomic Variants | 2 | 2019 | 33 | 0.070 |
Why?
| | Primary Health Care | 1 | 2019 | 1710 | 0.070 |
Why?
| | Drug Approval | 1 | 2008 | 89 | 0.070 |
Why?
| | Emergency Medical Services | 1 | 2015 | 696 | 0.070 |
Why?
| | Vasodilator Agents | 1 | 2010 | 331 | 0.070 |
Why?
| | Logistic Models | 1 | 2012 | 2104 | 0.060 |
Why?
| | Kidney Function Tests | 1 | 2007 | 157 | 0.060 |
Why?
| | Animals | 3 | 2023 | 38030 | 0.060 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 257 | 0.060 |
Why?
| | Zimbabwe | 2 | 2017 | 74 | 0.060 |
Why?
| | Drug Therapy, Combination | 1 | 2008 | 1044 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2026 | 3403 | 0.060 |
Why?
| | Opioid-Related Disorders | 1 | 2013 | 576 | 0.060 |
Why?
| | Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2025 | 36 | 0.050 |
Why?
| | Models, Biological | 1 | 2012 | 1820 | 0.050 |
Why?
| | Case-Control Studies | 1 | 2012 | 3592 | 0.050 |
Why?
| | Canada | 1 | 2026 | 428 | 0.050 |
Why?
| | Psychological Tests | 1 | 2005 | 131 | 0.050 |
Why?
| | Potassium Channels | 1 | 2025 | 145 | 0.050 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2004 | 40 | 0.050 |
Why?
| | Mandible | 1 | 2004 | 72 | 0.050 |
Why?
| | Depression | 2 | 2022 | 1533 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2022 | 5813 | 0.050 |
Why?
| | Receptors, Adrenergic | 1 | 2023 | 20 | 0.050 |
Why?
| | Drug Administration Schedule | 2 | 2020 | 778 | 0.050 |
Why?
| | Cardiovascular Agents | 1 | 2025 | 163 | 0.050 |
Why?
| | Carcinoembryonic Antigen | 1 | 2002 | 38 | 0.050 |
Why?
| | Antigens, Differentiation | 1 | 2002 | 77 | 0.050 |
Why?
| | Child | 5 | 2020 | 22537 | 0.040 |
Why?
| | Antigens, Bacterial | 1 | 2002 | 125 | 0.040 |
Why?
| | Electronic Prescribing | 1 | 2021 | 3 | 0.040 |
Why?
| | Cell Adhesion Molecules | 1 | 2002 | 177 | 0.040 |
Why?
| | Vitamin K Epoxide Reductases | 1 | 2020 | 11 | 0.040 |
Why?
| | Health Services Misuse | 1 | 2020 | 35 | 0.040 |
Why?
| | Antigens, Neoplasm | 1 | 2002 | 271 | 0.040 |
Why?
| | Insurance Claim Reporting | 1 | 2020 | 25 | 0.040 |
Why?
| | Antidepressive Agents | 1 | 2022 | 242 | 0.040 |
Why?
| | Lymphocyte Count | 1 | 2020 | 164 | 0.040 |
Why?
| | Morbidity | 1 | 2020 | 323 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2002 | 496 | 0.040 |
Why?
| | Metoprolol | 1 | 2019 | 26 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2010 | 2192 | 0.040 |
Why?
| | Grounded Theory | 1 | 2019 | 46 | 0.040 |
Why?
| | Bias | 1 | 2020 | 201 | 0.040 |
Why?
| | Aftercare | 1 | 2020 | 220 | 0.040 |
Why?
| | Antigens, CD | 1 | 2002 | 555 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 833 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2023 | 2182 | 0.030 |
Why?
| | Coronary Angiography | 1 | 2020 | 322 | 0.030 |
Why?
| | HIV Infections | 1 | 2013 | 3079 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 2002 | 2154 | 0.030 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2020 | 297 | 0.030 |
Why?
| | Static Electricity | 1 | 1997 | 113 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2002 | 2929 | 0.030 |
Why?
| | Exercise Test | 1 | 2020 | 634 | 0.030 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2017 | 103 | 0.030 |
Why?
| | Inpatients | 1 | 2021 | 542 | 0.030 |
Why?
| | Frail Elderly | 1 | 2017 | 133 | 0.030 |
Why?
| | Focus Groups | 1 | 2019 | 569 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2020 | 1312 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2017 | 341 | 0.030 |
Why?
| | World Health Organization | 1 | 2016 | 103 | 0.030 |
Why?
| | Metabolic Networks and Pathways | 1 | 2017 | 187 | 0.030 |
Why?
| | Puerperal Disorders | 1 | 2016 | 37 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 581 | 0.030 |
Why?
| | Neoplasms | 1 | 2010 | 2870 | 0.030 |
Why?
| | Decision Trees | 1 | 2015 | 81 | 0.030 |
Why?
| | Drug Combinations | 1 | 2016 | 390 | 0.030 |
Why?
| | Data Mining | 1 | 2015 | 117 | 0.030 |
Why?
| | Blood Pressure | 1 | 2020 | 1759 | 0.030 |
Why?
| | Cell Membrane | 1 | 1997 | 706 | 0.020 |
Why?
| | Biopsy | 1 | 2017 | 1075 | 0.020 |
Why?
| | Pediatrics | 1 | 2020 | 1112 | 0.020 |
Why?
| | Models, Genetic | 1 | 2015 | 535 | 0.020 |
Why?
| | Mass Screening | 2 | 2013 | 1332 | 0.020 |
Why?
| | Liver | 1 | 2020 | 1884 | 0.020 |
Why?
| | Infant | 2 | 2015 | 10022 | 0.020 |
Why?
| | Anthracyclines | 1 | 2010 | 47 | 0.020 |
Why?
| | Child, Preschool | 2 | 2015 | 11774 | 0.020 |
Why?
| | Trastuzumab | 1 | 2010 | 118 | 0.020 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2010 | 114 | 0.020 |
Why?
| | Signal Transduction | 1 | 2023 | 5221 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 1050 | 0.020 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 221 | 0.020 |
Why?
| | Program Evaluation | 1 | 2013 | 946 | 0.020 |
Why?
| | Apoptosis | 1 | 2017 | 2430 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2007 | 200 | 0.020 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2007 | 109 | 0.020 |
Why?
| | Ultrasonography | 1 | 2010 | 768 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2007 | 423 | 0.020 |
Why?
| | Mice | 1 | 2023 | 18329 | 0.010 |
Why?
| | Creatinine | 1 | 2007 | 505 | 0.010 |
Why?
| | Hospitals, University | 1 | 2005 | 176 | 0.010 |
Why?
| | Dentists | 1 | 2004 | 21 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2010 | 985 | 0.010 |
Why?
| | Femur Neck | 1 | 2004 | 62 | 0.010 |
Why?
| | Bone Diseases, Metabolic | 1 | 2004 | 56 | 0.010 |
Why?
| | Absorptiometry, Photon | 1 | 2004 | 275 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 1519 | 0.010 |
Why?
| | Nurses | 1 | 2005 | 178 | 0.010 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2002 | 24 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2004 | 1304 | 0.010 |
Why?
| | Bone Density | 1 | 2004 | 482 | 0.010 |
Why?
| | HeLa Cells | 1 | 2002 | 650 | 0.010 |
Why?
| | Binding Sites | 1 | 2002 | 1327 | 0.010 |
Why?
| | Clinical Competence | 1 | 2005 | 1241 | 0.010 |
Why?
| | Physicians | 1 | 2005 | 938 | 0.010 |
Why?
|
|
Kao's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|